<DOC>
	<DOCNO>NCT01379430</DOCNO>
	<brief_summary>The purpose trial ass safety immunogenicity AdCh63 ME-TRAP MVA ME-TRAP candidate vaccine healthy adult volunteer malaria endemic region . The regime propose trial protect non-immune volunteer sporozoite challenge clinical trial perform Oxford , may protective naturally acquire infection Kenya.The study population comprise 30 healthy adult male age 18-50 . The investigator propose include placebo group . At stage investigator objective describe safety profile small number individual , confidence interval proportion individual particular event would wide meaningful comparison placebo group . Immunogenicity judge comparison baseline .</brief_summary>
	<brief_title>Safety Immunogenicity AdCh63 ME-TRAP MVA ME-TRAP Vaccines Malaria Endemic Areas</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Consenting adult male age 1850 year good health . Will remain resident study area study duration Clinically significant history follow condition ; skin disorder ( eczema , etc . ) , allergy , symptomatic immunodeficiency , cardiovascular disease , respiratory disease , endocrine disorder , liver disease , renal disease , gastrointestinal disease , neurological illness . History splenectomy Haemoglobin le 9.0 g/dl Clinically significant abnormality laboratory screen test ( full blood count , ALT , creatinine level , urine dipstick examination blood protein ) . Blood transfusion within one month begin study History vaccination previous experimental malaria vaccine Administration vaccine immunoglobulin within two week vaccination . Current participation another clinical trial , within 12 week study Any finding opinion investigator would increase risk adverse outcome participation trial . Likelihood travel away study area HIV positive . History contact dermatitis ( due use potentially irritant disinfectant may present trace amount AdCh63 METRAP vaccine , see investigator brochure detail , attach )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Vaccine</keyword>
	<keyword>Immune response</keyword>
</DOC>